Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
WebMD13h
Diabetes Resource Center
Diabetes is a number of diseases that involve problems with the hormone insulin. There is no cure for diabetes. The warning signs of diabetes can be so mild that you don't notice them. That's ...